Pacific Biosciences of California, Inc. reports results for the quarter ended September 30 - Earnings Summary

• Pacific Biosciences of California, Inc. reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -13 cents. The mean expectation of eight analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -24 cents to -12 cents per share.

• Revenue rose 5.5% to $40.56 million from a year ago; analysts expected $40.39 million.

• Pacific Biosciences of California, Inc.'s reported EPS for the quarter was a loss of 12 cents​.

• The company reported a quarterly loss of $37.85 million.

• Pacific Biosciences of California, Inc. shares had risen by 3.0% this quarter and gained 30.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 19.3% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

• Wall Street's median 12-month price target for Pacific Biosciences of California, Inc. is $3.00, about 18.7% above its last closing price of $2.44

This summary was machine generated from LSEG data November 4 at 10:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)